Gamma-linolenic acid for attention-deficit hyperactivity disorder: Placebo-controlled comparison to d-amphetamine

Arnold, L. Eugene; Kleykamp, Donald; Votolato, Nicholas A.; Taylor, W.A.; Kontras, Stella B.; Tobin, Karen

doi:10.1016/0006-3223(89)90167-4

Cited by 96 publications

(64 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…38 This study reported significant improvements in the treatment group compared with the placebo group for both hyperactivity and psychiatrist-assessed global ratings. Owing to the poor reporting of some methodological criteria, the results from this study should be interpreted with caution.…”

Section: Discussionmentioning

confidence: 69%

“…Arnold and colleagues 38 also reported that global ratings, as assessed by a psychiatrist, were improved in the treatment group compared with the placebo group ( p < 0.05) (see Appendix 12).…”

Section: Quality Of Lifementioning

confidence: 94%

“…Arnold and colleagues 38 reported that DEX time-release capsules were significantly better than placebo using the Hyperactivity Index of the CTRS ( Table 35).…”

Section: Hyperactivitymentioning

confidence: 99%

“…Generally, this study rated well in the quality assessement. An additional study by Arnold and colleagues 38 evaluated DEX-TR compared with placebo. They observed significant improvements in hyperactivity with treatment.…”

Section: Dex Versus Placebomentioning

confidence: 99%

See 3 more Smart Citations

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

King

Griffin²,

Hodges³

et al. 2006

Health Technol Assess

144

117

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA Programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS,...

show abstract

Section: Discussionmentioning

confidence: 69%

Section: Quality Of Lifementioning

confidence: 94%

“…Arnold and colleagues 38 reported that DEX time-release capsules were significantly better than placebo using the Hyperactivity Index of the CTRS ( Table 35).…”

Section: Hyperactivitymentioning

confidence: 99%

Section: Dex Versus Placebomentioning

confidence: 99%

See 2 more Smart Citations

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

King

Griffin²,

Hodges³

et al. 2006

Health Technol Assess

144

117

View full text Add to dashboard Cite

show abstract

“…Five studies compared some form of psychological or behavioral intervention versus medication, 6,7,37-40 and 1 study compared DEX and the dietary supplement Efamol (Efamol Ltd, North Yorkshire, United Kingdom). 41 The evidence review noted that these studies, with the exception of the study by the MTA Cooperative Group, provided insufficient detail regarding the interventions and methodology and much heterogeneity in the type of nondrug intervention and outcomes assessed. The MTA Cooperative Group provided much more detail regarding its clinical interventions and outcome measures.…”

Section: Pharmacologic Versus Nonpharmacologic Interventionsmentioning

confidence: 99%